NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients With Bipolar Depression With Acute Suicidality
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need
Company received Breakthrough Therapy Designation and a Special Protocol